If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Further statement re claim filed by RB

30 Nov 2020 07:00

RNS Number : 8416G
Indivior PLC
30 November 2020
 

Indivior is providing the following statement pursuant to its initial statement dated November 27, 2020, related to a claim filed against it by Reckitt Benckiser Group.

 

Indivior PLC ("Indivior" or "the Company"), as an entitled party, has reviewed the claim Reckitt Benckiser Group ("RB") filed against the Company in the Commercial High Court in London on November 13, 2020. At the present time, the claim has not been served on the Company. Indivior notes reported comments by RB, as published in The Times and Financial Times newspapers on November 27, 2020, that RB "regularly takes certain procedural steps to preserve potential claims."

 

Based on the information available to it, Indivior strongly believes that the claim is without merit and that it has strong grounds for defending against the claim should it be served. If the claim is served, Indivior will fully and vigorously defend itself in any proceedings related to the claim.

 

Indivior will make further announcements as appropriate, including in relation to whether the claim is served.

 

 

For Further Information

Investor Enquiries

 

Jason Thompson

VP, Investor Relations Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

Media Enquiries

Jonathan Sibun 

Tulchan Communications

US Media Inquiries

 

+44 207 353 4200 

+1 804 594 0836

Indiviormediacontacts@indivior.com

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURBLBMTMTITTTM
Date   Source Headline
28th Feb 20259:43 amRNSDirector/PDMR Shareholding
28th Feb 20259:42 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSHolding(s) in Company
27th Feb 20254:31 pmRNSDirector/PDMR Shareholding
27th Feb 20254:29 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSJoseph Ciaffoni Appointed Chief Executive Officer
25th Feb 20257:00 amRNSHolding(s) in Company
24th Feb 20257:00 amRNSFDA Approval of SUBLOCADE Label Changes
20th Feb 20257:00 amRNSFinal Results
12th Feb 20257:00 amRNSDelayed FDA Approval of SUBLOCADE Label Changes
4th Feb 20253:12 pmRNSNotice of Results
4th Feb 20257:00 amRNSCompletion of Share Repurchase Program
4th Feb 20257:00 amRNSTransaction in Own Shares
3rd Feb 20259:26 amRNSTotal Voting Rights
3rd Feb 20257:00 amRNSAppointment of Independent Non-Executive Director
28th Jan 20253:30 pmRNSDr. David Wheadon appointed Chair of the Board
28th Jan 20259:43 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSTransaction in Own Shares
27th Jan 20259:08 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTransaction in Own Shares
16th Jan 20254:00 pmRNSReplacement Transaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20251:00 pmRNSIndivior Provides Historical Financials in US GAAP
7th Jan 20258:55 amRNSHolding(s) in Company
7th Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20259:31 amRNSTotal Voting Rights
31st Dec 20249:53 amRNSHolding(s) in Company
31st Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 202410:32 amRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSIndivior Announces Changes to Board of Directors
17th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20249:44 amRNSTotal Voting Rights
26th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSIndivior to Participate in Upcoming Investor Event
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20248:48 amRNSHolding(s) in Company
15th Nov 20247:00 amRNSDirector Declaration
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20242:29 pmRNSHolding(s) in Company
8th Nov 20244:50 pmRNSBlock listing Interim Review
8th Nov 20247:00 amRNSIndivior Responds to Letter from Oaktree
5th Nov 20247:00 amRNSIndivior Completes Refinance of Secured Term Loan
5th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202411:59 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNS3rd Quarter Results
22nd Oct 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.